Legal Representation
Attorney
Nancy Sabarra
USPTO Deadlines
Next Deadline
15 days remaining
NOA E-Mailed - SOU Required
Due Date
January 04, 2026
Extension Available
Until July 04, 2026
Application History
34 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 27, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 26, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jun 26, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jun 26, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 4, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 3, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jan 2, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 2, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 6, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jun 6, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jun 6, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 21, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 19, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 19, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Dec 19, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 4, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 9, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 9, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 19, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 5, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 5, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Apr 5, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Apr 5, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Apr 5, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 30, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 30, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 30, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 30, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 30, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 30, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 23, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 11, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 8, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use
Class 005
Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells
Class 042
Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines
Class 044
Medical services; medical information; providing a website featuring medical information
Classification
International Classes
001
005
042
044